These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37440274)

  • 21. Stable Isotope Tracer Technique and Network Pharmacology to Reveal Antidepressant Targets and Active Components of Xiaoyao San.
    Tian J; Wang X; Wu W; Zhao Y; Ling-Hu T; Qin X
    Chem Biodivers; 2024 Apr; 21(4):e202301736. PubMed ID: 38451006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of the Potential Mechanism of Danggui Shaoyao San for the Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) with Network Pharmacology and Molecular Docking.
    Cheng F; Li Q; Wang J; Zeng F; Zhang Y
    Curr Comput Aided Drug Des; 2022; 18(4):258-270. PubMed ID: 36043707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Research into the anti-pulmonary fibrosis mechanism of Renshen Pingfei formula based on network pharmacology, metabolomics, and verification of AMPK/PPAR-γ pathway of active ingredients.
    Yan L; Jiang MY; Fan XS
    J Ethnopharmacol; 2023 Dec; 317():116773. PubMed ID: 37308028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism investigation of anti-NAFLD of Shugan Yipi Granule based on network pharmacology analysis and experimental verification.
    Li H; Niu L; Wang M; Liu C; Wang Y; Su Y; Yang Y
    Heliyon; 2024 Aug; 10(15):e35491. PubMed ID: 39170438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated Plasma Metabolomics and Gut Microbiota Analysis: The Intervention Effect of Jiawei Xiaoyao San on Liver Depression and Spleen Deficiency Liver Cancer Rats.
    Li Z; Zhao Y; Cheng J; Xu L; Wen X; Sun Y; Xia M; He Y
    Front Pharmacol; 2022; 13():906256. PubMed ID: 35924041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive pharmacological and experimental study of Ginsenoside Re as a potential therapeutic agent for non-alcoholic fatty liver disease.
    Zhang J; Duan M; Wu S; Jiang S; Hu S; Chen W; Zhang J; Quan H; Yang W; Wang C;
    Biomed Pharmacother; 2024 Aug; 177():116955. PubMed ID: 38906030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study on the mechanism of Shuganzhi Tablet against nonalcoholic fatty liver disease and lipid regulation effects of its main substances in vitro.
    Tang J; Wang L; Shi M; Feng S; Zhang T; Han H
    J Ethnopharmacol; 2023 Nov; 316():116780. PubMed ID: 37311504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study on the action mechanism of the Polygonum perfoliatum L. on non-alcoholic fatty liver disease, based on network pharmacology and experimental validation.
    Liu G; Yang L; Tang Y; Lin J; Wang F; Shen J; Chang B; Kong X
    J Ethnopharmacol; 2024 Jan; 319(Pt 3):117330. PubMed ID: 37863399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Network pharmacological analysis on the mechanism of Linggui Zhugan decoction for nonalcoholic fatty liver disease.
    Gao S; Wei L; Qin Y; Zhang P; Quan T; Liang F; Huang G
    Medicine (Baltimore); 2024 Mar; 103(10):e37281. PubMed ID: 38457573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacological actions of Danzhi-xiaoyao-San on depression involve lysophosphatidic acid and microbiota-gut-brain axis: novel insights from a systems pharmacology analysis of a double-blind, randomized, placebo-controlled clinical trial.
    Zhu X; Wu S; Zhou Y; Xiao T; Xia L; Wang Y; Xiao A; Guo J; Zhang M; Wen Y; Shang D; Yu L
    J Biomol Struct Dyn; 2024 Nov; 42(18):9309-9324. PubMed ID: 37632305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism Study of Xiaoyao San against Nonalcoholic Steatohepatitis-Related Liver Fibrosis Based on a Combined Strategy of Transcriptome Analysis and Network Pharmacology.
    Yan D; Zhang X; Ma C; Huang W; Hao M; Xie L
    Pharmaceuticals (Basel); 2024 Aug; 17(9):. PubMed ID: 39338294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The synergistic anti-depression effects of different efficacy groups of Xiaoyaosan as demonstrated by the integration of network pharmacology and serum metabolomics.
    Liu XJ; Wang YZ; Wei FX; Lv M; Qu P; Chen SJ; Li SY; Qin X
    J Pharm Biomed Anal; 2021 Apr; 197():113949. PubMed ID: 33618131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of the kynurenine metabolism pathway by Xiaoyao San and the underlying effect in the hippocampus of the depressed rat.
    Wang J; Li X; He S; Hu L; Guo J; Huang X; Hu J; Qi Y; Chen B; Shang D; Wen Y
    J Ethnopharmacol; 2018 Mar; 214():13-21. PubMed ID: 29217494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The active components and potential mechanisms of Wuji Wan in the treatment of ethanol-induced gastric ulcer: An integrated metabolomics, network pharmacology and experimental validation.
    Wu T; Zhang H; Jin Y; Zhang M; Zhao Q; Li H; Wang S; Lu Y; Chen S; Du H; Liu T; Guo W; Liu W
    J Ethnopharmacol; 2024 May; 326():117901. PubMed ID: 38341112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Xiaoyao San, a Chinese herbal formula, ameliorates depression-like behavior in mice through the AdipoR1/AMPK/ACC pathway in hypothalamus.
    Tang KR; Mo XW; Zhou XY; Chen YY; Liu DD; He LL; Ma QY; Li XJ; Chen JX
    J Integr Med; 2022 Sep; 20(5):442-452. PubMed ID: 35906133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
    Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
    J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanism of Ginkgo biloba in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease based on network pharmacology, molecular docking, and experimental evaluations.
    Xu S; Tang L; Qian X; Wang Y; Gong J; Yang H; Su D
    J Food Biochem; 2022 Dec; 46(12):e14419. PubMed ID: 36121703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identify Molecular Mechanisms of Jiangzhi Decoction on Nonalcoholic Fatty Liver Disease by Network Pharmacology Analysis and Experimental Validation.
    Wang L; Zhi Y; Ye Y; Zhang M; Ma X; Tie H; Ma X; Zheng N; Xia W; Song Y
    Biomed Res Int; 2020; 2020():8829346. PubMed ID: 33415161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integration of network pharmacology and experimental verification to reveal the active components and molecular mechanism of modified Danzhi Xiaoyao San in the treatment of depression.
    Wu M; Yan X; Huang H; Guo X; Bai M; Wang B; Su P; Li Y; Xu E
    J Ethnopharmacol; 2025 Jan; 336():118739. PubMed ID: 39197805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Network Pharmacology and Molecular Docking to Unveil the Mechanism of Shudihuang against Amyotrophic Lateral Sclerosis.
    Li X; Tian Y; Wu H; Wang T
    Curr Pharm Des; 2023; 29(19):1535-1545. PubMed ID: 37345246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.